Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 10 recruiting now official registry

Colitis, Ulcerative clinical trials

10 of 29 indexed Colitis, Ulcerative trials are currently recruiting.

29 US clinical trials · 10 currently recruiting

Colitis, Ulcerative is the subject of 29 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 12 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is Janssen Research & Development, running 10 of these trials.

The research picture

Colitis, Ulcerative has 29 registered US clinical trials, 10 of them open to new participants right now, about 34% of the total.

10
recruiting participants now
34%
of trials open to enrollment
12
in Phase 3–4 (later-stage)
10
top sponsor: Janssen Research & Development
Phase 11Phase 213Phase 39Phase 43

Active & Recent Trials

29 total, page 1 of 1

RECRUITING Phase 3 1,380 participants

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

Merck Sharp & Dohme

NCT06651281

RECRUITING 1,056 participants

A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis

Janssen Scientific Affairs

NCT04372108

RECRUITING Phase 3 882 participants

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

Janssen Research & Development

NCT07196748

RECRUITING Phase 2 645 participants

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

Spyre Therapeutics

NCT07012395

RECRUITING 300 participants

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

Pfizer

NCT06398626

RECRUITING Phase 2 204 participants

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis

Sanofi

NCT06867094

RECRUITING Phase 3 196 participants

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

Janssen Research & Development

NCT06663332

RECRUITING Phase 2 120 participants

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

Bristol-Myers Squibb

NCT05076175

RECRUITING 60 participants

Therapeutic Endpoint in Pediatric IBD Conditions

Children's National Research Institute

NCT06065228

RECRUITING Phase 2 40 participants

Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients

University of California, San Diego

NCT04721873

ACTIVE NOT RECRUITING Phase 4 672 participants

Determination of the Optimal Treatment Target in Ulcerative Colitis

Alimentiv

NCT04259138

ACTIVE NOT RECRUITING Phase 2 577 participants

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Janssen Research & Development

NCT05242484

ACTIVE NOT RECRUITING Phase 3 418 participants

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Janssen Research & Development

NCT05528510

ACTIVE NOT RECRUITING Phase 2 280 participants

A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

NCT05611671

ACTIVE NOT RECRUITING Phase 2 247 participants

A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

Teva Branded Pharmaceutical Products R&D

NCT05668013

ACTIVE NOT RECRUITING Phase 2 213 participants

VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

Oppilan Pharma

NCT05156125

ACTIVE NOT RECRUITING Phase 2 187 participants

Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

Sanofi

NCT05588843

ACTIVE NOT RECRUITING Phase 3 159 participants

A Long-term Extension Study of Ustekinumab in Pediatric Participants

Janssen Research & Development

NCT05092269

ACTIVE NOT RECRUITING Phase 3 112 participants

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

Janssen Research & Development

NCT06260163

ACTIVE NOT RECRUITING Phase 3 84 participants

A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

Janssen Research & Development

NCT03596645

ACTIVE NOT RECRUITING Phase 2 68 participants

A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

Sanofi

NCT05731128

COMPLETED Phase 2 1,065 participants

An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis

Janssen Research & Development

NCT00487539

COMPLETED Phase 3 961 participants

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Janssen Research & Development

NCT02407236

COMPLETED Phase 3 771 participants

An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

Takeda

NCT02497469

COMPLETED Phase 2 290 participants

A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

Teva Branded Pharmaceutical Products R&D

NCT05499130

COMPLETED Phase 4 278 participants

Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis

Takeda

NCT03029143

COMPLETED Phase 2 50 participants

Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.

Telavant

NCT02840721

COMPLETED Phase 1 35 participants

A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis

Janssen Research & Development

NCT01900574

COMPLETED Phase 4 11 participants

Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease

Takeda

NCT02559713

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 13
Phase 3 9
Phase 4 3

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Colitis, Ulcerative Trial Landscape

29 indexed Colitis, Ulcerative studies · 10 recruiting (34%).

Phase mix: 12 late (III/IV) vs 14 early (I/II).

Top sponsor: Janssen Research & Development (10 trials), 9 others listed. 29 shown below, recruiting first.

How to read this condition's trial landscape

That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Colitis, Ulcerative?

PlainTrial tracks 29 US clinical trials for Colitis, Ulcerative, of which 10 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Colitis, Ulcerative?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.